• Video
    lock
    Disease Awareness / Video
    Managing the TSC Transition to Adult Care

    Ann describes how to live with symptoms as an adult living with Tuberous Sclerosis Complex (TSC) .

  • Image
    lock
    Leadership / Image
    Rob Kowalski

    Chief People & Organization Officer of Novartis

  • PDF
    lock
    Products / Infographic
    Interleukin 17-A (IL-17A) in Psoriasis

    A cornerstone cytokine (messenger protein) involved in the development of psoriasis and other autoimmune diseases.

  • PDF
    lock
    Products / Infographic
    Interleukin 17-A (IL-17A) in Inflammatory Joint Disease

    IL-17A helps fight infection but in chronic inflammatory joint diseases, IL-17A is a key cytokine involved in disease development.

  • Image
    lock
    Products / Image
    Kymriah™ (tisagenlecleucel) suspension for intravenous infusion

    Photo of Kymriah™ (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019.

  • PDF
    lock
    Products / Fact Sheet
    RTH258 Brolucizumab Clinical Trials

    Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.

  • PDF
    lock
    Products / Fact Sheet
    Kymriah™(tisagenlecleucel) in children and young adults with B-cell ALL that is refractory or relapsed at least twice

    Kymriah (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US

  • PDF
    lock
    Products / Fact Sheet
    The JULIET Clinical Trial

    The JULIET clinical trial is a global, multi-center Phase II registration trial investigating CTL019 (tisagenlecleucel) for use in diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL). The Novartis-sponsored JULIET trial was conducted in collaboration with the University of Pennsylvania to evaluate the safety and efficacy of CTL019 in adult patients with relapsed or refractory (r/r) DLBCL. Relapsed/refractory DLBCL is an aggressive (fast-growing), complex and difficult-to-treat disease, and patients with DLBCL often have worse prognosis than other forms of NHL.

  • PDF
    lock
    Products / Fact Sheet
    How does ACZ885 work?

    ACZ885 is a human monoclonal antibody, which is a protein that is designed to bind to only one substance in the body. ACZ885 is designed to bind to human interleukin-1β (IL-1β).

  • PDF
    lock
    Products / Fact Sheet
    Erenumab (AMG 334) Key Clinical Trials By The Numbers

    Erenumab has been studied in several large, global, randomized, double-blind, placebo-controlled studies to assess its safety and efficancy in migraine prevention.

  • PDF
    lock
    Products / Fact Sheet
    About erenumab AMG 334

    Erenumab is designed to specifically block the CGRP receptor, which plays a critical role in migraine activation. It is being co-developed by Novartis and Amgen.

  • Video
    lock
    Corporate Responsibility / Video
    What do you know about noncommunicable diseases?

    The menace of noncommunicable diseases (NCDs) like cardiovascular disease, diabetes and cancer in the developing world is increasing. New solutions like Novartis Access are needed to ensure more people are trained to prevent, diagnose and treat these diseases, and patients have access to affordable quality medicines.